港股點評 2026年2月5日9:30 a.m 恒指升 12 點，滬指升 51 點，標普 500 跌 35 點 港股表現反覆。恒指低開 37 點，初段曾跌 241 點一度低見 26,593 點，午市曾升 169 點高見 27,004 點，全日升 12 點或 0.05%，收 26,847 點；國指跌 4 點或 0.05%， 報 9,048 點；恒生科指跌 100 點或 1.8%，收 5,366 點。大市全日成交總額降至 2,854.33 億元。 人民銀行 4 日在公開市場開展 750 億元人民幣七天期逆回購操作，操作利率持 平於 1.4%。有 3,775 億元逆回購到期，單日淨回籠 3,025 億元。為保持銀行體系 流動性充裕，人民銀行開展 8,000 億元買斷式逆回購操作，期限為三個月。A 股 三大指數先跌後個別發展，滬指反覆穩升，創板午後跌幅收窄。滬綜指全日收 升 34 點或 0.9%，報 4,102 點，成交 1.06 萬億元。深成指全日收升 29 點或 0.2%， 報 14,156 點，成交 1.42 萬億元。創板指數全日收跌 13 點或 0.4%，報 3,311 點， 成交 6,756 億元。 供應管理 ...

Market Overview - The Hang Seng Index is expected to hold at 26,000 points, influenced by the hawkish stance of the newly appointed Federal Reserve Chairman and a rebound in the US dollar index, which has led to market adjustments in commodities [2] - The Chinese GDP growth target for 2026 is anticipated to be set between 4.5% and 5%, lower than the previous target of around 5% for 2025, as local governments have begun to lower their GDP targets ahead of the Two Sessions [2] - Regulatory measures have been implemented to cool the market, including increased financing margin ratios on the Shanghai and Shenzhen stock exchanges, which has led to a collective reduction in leverage across the three markets [2] Sector Focus - Macau gaming stocks are favored in the short term due to January's gambling revenue exceeding expectations, with the upcoming Spring Festival serving as a catalyst for growth [3] Macro Focus - China's January RatingDog services PMI rose to 52.3, indicating an acceleration in service sector expansion, with new export orders showing strong growth [7] - The People's Bank of China emphasizes the need to support domestic demand and technological innovation in its 2026 credit market work [7] - The US ADP reported a lower-than-expected increase of 22,000 private sector jobs in January, indicating potential labor market weaknesses [7] Company News - Walden Materials (9981) is launching an IPO to raise approximately HKD 28 billion, with a share price capped at HKD 20.09 [9] - Baidu Group (9888) plans to repurchase USD 5 billion in shares and will announce its first dividend this year [9] - Meituan (3690) and Tencent (0700) are taking measures to regulate promotional activities on their platforms, reflecting a tightening of marketing practices [9] - BYD (1211) reported a tenfold increase in electric vehicle sales in Germany, significantly outperforming Tesla [9] - Tesla (TSLA.US) saw a 9.3% increase in electric vehicle sales in China but a 57% drop in the UK market [9]

截至2026年2月5日 09:41，中证港股通医药卫生综合指数(930965)上涨0.32%，成分股银诺医药-B上涨 10.07%，药明康德上涨2.73%，海吉亚医疗上涨2.65%，再鼎医药上涨2.13%，四环医药上涨1.89%。港 股医药ETF(159718)下跌0.22%，最新报价0.92元。 消息面上，政策持续支持医药产业，国家药监局称，"十五五"期间将大力支持生物制造产业创新发展。 港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选 取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫 生上市公司证券的整体表现。 数据显示，截至2026年1月30日，中证港股通医药卫生综合指数(930965)前十大权重股分别为药明生 物、百济神州、信达生物、康方生物、京东健康、石药集团、中国生物制药、翰森制药、药明康德、三 生制药，前十大权重股合计占比64.57%。 港股医药ETF(159718)，场外联接(平安中证港股医药ETF联接A：019598；平安中证港股医药ETF联接 C：019599；平安中证港股医药ETF联接E：024544 ...

信达生物2月4日公布其2025全年业绩，总产品收入约人民币119亿元，同比保持约45%的强劲增长态 势。2025年Q4，信达生物有6款新药纳入2026年国家医保目录。 东海证券表示，2025年创新药板块进入盈利兑现提速期，诺诚健华、荣昌生物等实现扭亏为盈，三生国 健等业绩大幅预增，君实生物等显著减亏，核心驱动主要来自商业化产品快速放量和BD合作两大主 线。 2月5日早盘，港股市场主要指数集体下挫，聚焦创新药、AI医疗主线的港股通医疗ETF(520510)一度逆 势翻红，脑动极光、药明康德（603259）、凯莱英（002821）等持仓股涨幅靠前。 ...

Market Overview - The Hong Kong stock market opened lower on February 5, with the Hang Seng Index down 219.37 points, a decline of 0.82%, closing at 26,627.95 points [1] - The Hang Seng Tech Index fell by 70.55 points, down 1.31%, to 5,295.89 points [1] - The China Enterprises Index decreased by 69.92 points, a drop of 0.77%, to 8,978.46 points [1] - The Red Chip Index declined by 8.89 points, down 0.2%, to 4,363.4 points [1] - The previous day saw mixed performance among the three major indices, with the Hang Seng Index closing in the green while the Hang Seng Tech Index experienced a drop of over 2% at one point [1] Company Performance - Xinda Biologics (01801.HK) reported a projected total product revenue of approximately RMB 11.9 billion for 2025, reflecting a year-on-year growth of about 45% [2] - Lee & Man Paper Manufacturing (02314.HK) anticipates a profit of approximately HKD 1.88 billion to HKD 2.00 billion for 2025, representing a year-on-year increase of 38% to 47% [2] - ZTO Express (02057.HK) expects total revenue for 2025 to be between RMB 48.5 billion and RMB 50 billion, with a year-on-year growth of about 9.5% to 12.9% due to increased parcel volume [2] - China Resources Cement (01313.HK) forecasts a year-on-year profit increase of approximately 115% to 135% for 2025, driven by cost reductions and decreased impairment losses [2] - Gemdale Corporation (00535.HK) reported a total contract sales amount of approximately RMB 239 million in January, a year-on-year decrease of 61.82% [3] - Fosun International (00656.HK) plans to subscribe to additional registered capital of Shangan Technology for RMB 105 million, acquiring a 51.0879% stake post-capital increase [3] - Shanghai Pharmaceuticals (02607.HK) intends to transfer its 30% stake in Amgen for a minimum listing price of approximately RMB 1.023 billion [3] Corporate Actions - Caocao Travel (02643.HK) completed a placement of 12 million shares at HKD 32.46 per share, raising approximately HKD 383 million [4] - Kingsoft (03888.HK) repurchased 1.0886 million shares for HKD 29.99 million, with repurchase prices ranging from HKD 27.18 to HKD 28 [5] - Xiaomi Group (01810.HK) spent HKD 146 million to repurchase 4.3 million shares at prices between HKD 33.94 and HKD 34.02 [6] - Kingdee International (00268.HK) repurchased 1 million shares for HKD 11.0597 million, with prices between HKD 11.05 and HKD 11.1 [7] Industry Insights - Guosen Securities remains optimistic about the spring market, suggesting a focus on performance-based investments despite potential negative impacts from the rebound of the US dollar index and rising US Treasury yields [8] - CICC noted advancements in global large model technology capabilities, particularly in reasoning and programming, while highlighting ongoing limitations in general capabilities [9] - Xinda Securities pointed out the continuous improvement of regulations in the domestic intelligent connected vehicle sector, with an expected market size of RMB 270 billion for Robo-taxis by 2030 and a projected increase in the logistics vehicle industry value to RMB 594.8 billion by 2030 [9]

Strategy Research - The macroeconomic landscape shows a divergence in performance, with strong demand for technology hardware driven by AI infrastructure investment, while chemical prices remain robust due to supply constraints [2][3] - High-end liquor prices are stabilizing, indicating some recovery in consumer spending, although the sustainability of this trend remains uncertain [3][4] Food and Beverage Research - The company Sobo Protein is expected to maintain rapid profit growth in Q4 2025, with projected net profit for 2025 ranging from 178 to 191 million yuan, reflecting a year-on-year increase of 46.89% to 57.62% [8][36] - The company is focusing on high-end manufacturing and energy optimization, which is expected to enhance profitability [37] Automotive Research - The Robotaxi market in China is projected to reach a value of 50 billion yuan, with hardware cost reductions and software iterations driving demand [11][29] - The commercial viability of Robotaxi is approaching a critical point, with both L2 and L4 participants accelerating market penetration [11][29] Consumer Sector - The price of high-end liquor, such as Moutai, has increased by 3.9% for original and 3.0% for bulk, likely due to pre-holiday gifting demand [4][16] - The real estate market remains weak, with significant declines in transaction volumes across major cities, although policies to stabilize the market are being implemented [4][16] Technology and Manufacturing - The price of DRAM storage has shown signs of stabilization, with a slight decrease in DDR4 prices and a slight increase in DDR5 prices, while overall prices remain high [5][17] - Chemical prices continue to be strong, with PX prices increasing by 5.2% [5][17] Logistics and Transportation - Passenger transport demand remains stable ahead of the holiday season, with a slight increase in logistics demand reflected in highway and rail freight volumes [18] - Shipping rates have shown mixed trends, with domestic port throughput increasing, indicating a potential recovery in export activity [18] Industry Tracking: Machinery - The company Hangzhou Steam Turbine has signed its first commercial contract for a self-developed gas turbine, marking a significant step towards industrial application [19][20] - The company is also advancing its "B to A" strategy to enhance financing channels for high-investment R&D projects [21] Industry Research: Pharmaceuticals - The total market value of publicly held pharmaceutical stocks decreased from 397.7 billion to 316.1 billion yuan, indicating a decline in investor confidence [23][24] - The chemical preparation sector remains the largest segment within pharmaceutical holdings, accounting for 37.5% of total holdings [23] Industry Research: Information Technology - The median profit growth for computer companies is significantly higher than revenue growth, indicating a trend of improving profitability despite stagnant sales [25][26] - A notable number of companies are experiencing significant profit declines, highlighting a polarized performance within the sector [26][28]

盘前要闻 1、国家主席习近平同美国总统特朗普通电话 类型：宏观 情绪影响：正面 2月4日晚，国家主席习近平同美国总统特朗普通电话。习近平指出，今年中美两国各自都有不少重要议 程，中国"十五五"开局起步，美国将迎来建国250周年，双方要按照我们达成的共识，加强对话沟通， 妥善管控分歧，拓展务实合作，让2026年成为中美两个大国迈向相互尊重、和平共处、合作共赢的一 年。 2、马斯克团队光伏调研消息引爆A股！多家巨头回应最新进展 类型：行业 情绪影响：正面 据报道，上周马斯克团队已对包括TCL中环、晶科能源、晶盛机电等在内的多家中国光伏企业调研，考 察覆盖设备、硅片等多个环节。对此，晶科能源表示尚未就此发布官方公告。晶盛机电相关负责人表 示"并不清楚"公司是否在调研范围内。高测股份证实公司确与马斯克团队有过接触，但明确目前双方尚 未达成任何合作。 3、央行：着力支持扩大内需、科技创新、中小微企业等重点领域 类型：市场 情绪影响：负面 美股市场软件股抛售潮继续蔓延至半导体、AI概念股等整个科技领域，资金从科技股中撤出，轮动至 能源、材料等价值板块。AI算力芯片公司AMD发布业绩后暴跌17.31%，AI应用股AppLo ...

【今日头条】 港交所CEO回应"港股IPO严控保荐质量" 香港证监会近日发出通函，表示高度关注在2025年新上市申请激增期间出现的问题，包括部分上市文件 的拟备工作存在严重缺失，保荐人或有失当行为，以及其资源管理严重失误。港交所CEO陈翊庭表示， 特别欢迎香港证监会出台该通函，认为这是一份"温馨提示"。陈翊庭强调，香港证监会关注的是保荐人 递交的材料质量，而非上市申请人自身的资料，二者互不相关。港交所始终将质量视为吸引全球投资者 的底气，在当前IPO申请势头良好的背景下，该通函能确保港交所维持高效的服务水平，市场也可以迎 接更多高质量IPO。。 国际油价02月04日上涨。截至当天收盘，纽约商品交易所WTI原油期货当月连续合约上涨1.26美元，收 于每桶64.47美元，涨幅为1.99%。COMEX黄金期货当月连续合约上涨51.40美元，涨幅1.04%，报 4986.4美元/盎司。COMEX白银期货当月连续合约上涨4.46美元，涨幅5.36%，报87.765美元/盎司。现货 黄金上涨17.27美元，涨幅0.35%，报4964.31美元/盎司。现货白银上涨3.12美元，涨幅3.67%，报88.2美 元/盎司。 【热 ...

Group 1 - Shanghai Pharmaceuticals plans to transfer 30% equity stake in China and America Bristol-Myers Squibb for no less than 1.023 billion yuan, aiming to optimize investment structure and achieve asset appreciation [1] - The net profit of the target company for the first three quarters of 2025 was 87.11 million yuan, and the transaction is not expected to have a significant impact, although uncertainties exist regarding the buyer [1] Group 2 - Pianzaihuang's controlling shareholder, Jiulongjiang Group, has received a loan commitment from Industrial and Commercial Bank of China for up to 450 million yuan to support the purchase of additional shares [2] - The controlling shareholder plans to use additional self-funding of 300 million to 500 million yuan for the share acquisition, reflecting confidence in the company's value [2] Group 3 - Qizheng Tibetan Medicine's subsidiary has received a registration certificate for the "Cui Tang Granules" from the Macau government, which is a traditional Chinese medicine for respiratory issues [3] - The approval is expected to help expand the company's presence in overseas markets, although it is not anticipated to have a significant impact on recent performance [3] Group 4 - Zhifei Biological's subsidiary has received approval for clinical trials of a freeze-dried varicella inactivated vaccine, which aims to prevent chickenpox and shingles [4] - The vaccine utilizes self-developed technology and fills a gap in the domestic inactivated vaccine market, but is not expected to have a major short-term impact on performance [4] Group 5 - Innovent Biologics forecasts total product revenue of approximately 11.9 billion yuan for 2025, marking a year-on-year growth of about 45% [5] - The company achieved approximately 3.3 billion yuan in total product revenue in the fourth quarter of 2025, with a year-on-year increase of over 60%, driven by steady growth in 13 oncology products and the release of 3 chronic disease medications [5]

经营业绩： 中通快递-W(02057)预计2025年收入总额485亿元至500亿元 同比增长约9.5%至12.9% 重大事项： 中通快递-W(02057)拟发售15亿美元的可换股优先票据 复星国际(00656)附属复星商发拟以1.05亿元认购商盟科技新增注册资本，对应取得商盟科技增资后 51.0879%的股权 上海医药(02607)：常州制药厂的西格列汀二甲双胍缓释片获得批准生产 中船防务(00317)控股子公司签订16 艘支线集装箱船建造合同 翰思艾泰-B(03378)：HX111完成首例病人用药 信达生物(01801)2025年实现总产品收入约119亿元 同比保持约45%的强劲增长态势 百胜中国(09987)2025年经营利润同比增长11%至13亿美元 华润建材科技(01313)发盈喜 预期2025年度股东应占盈利同比上升大约115%至135% 理文造纸(02314)发盈喜 预期2025年盈利约18.8亿港元至20.0亿港元 同比增长38%至47% 小马智行-W(02026)发盈喜 预期2025年净亏损约6900万美元至8600万美元 同比收窄 ...